Kinoshita, Yoshikazu
Kato, Mototsugu
Fujishiro, Mitsuhiro
Masuyama, Hironori
Nakata, Ryo
Abe, Hisanori
Kumagai, Shinji
Fukushima, Yasushi
Okubo, Yoshiumi
Hojo, Seiichiro
Kusano, Motoyasu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
https://doi.org/10.1007/s00535-017-1417-z
Funding for this research was provided by:
Eisai Co., Ltd.
EA Pharma Co., Ltd.
Article History
Received: 6 September 2017
Accepted: 17 November 2017
First Online: 29 November 2017
Compliance with ethical standards
:
: Yoshikazu Kinoshita received honoraria from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and AstraZeneca K.K., and received research grants from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and AstraZeneca K.K. Mototsugu Kato received honoraria from AstraZeneca K.K., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., and research grants from Abbott Japan Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd. and Astellas Pharma Co., Ltd. Mitsuhiro Fujishiro received honoraria from HOYA Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneka K.K., Zeria Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd., and received research grants from Takeda Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd. Hironori Masuyama received research grants from Eisai Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Yoshiumi Okubo is an employee of EA Pharma Co., Ltd. Seiichiro Hojo is an employee of Eisai Co., Ltd. Motoyasu Kusano received honoraria and research grants from Eisai Co., Ltd., EA Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., TSUMURA & CO., Zeria Pharmaceutical Co., Ltd. and Astellas Pharma Co., Ltd. The following authors declare that they have no conflict of interest: Ryo Nakata, Hisanori Abe, Shinji Kumagai, and Yasushi Fukushima.
: This study was funded by Eisai, Co., Ltd., Tokyo, Japan and EA Pharma Co., Ltd., Tokyo, Japan. The writing and preparation of this paper were funded in part by EA Pharma. Writing support was provided by Eisai. Data analyses were undertaken by Eisai.